WO2023112974A1 - Agent réduisant l'hypertension contenant un extrait d'algue, et aliment fonctionnel, quasi-médicament et médicament contenant l'agent réduisant l'hypertension - Google Patents

Agent réduisant l'hypertension contenant un extrait d'algue, et aliment fonctionnel, quasi-médicament et médicament contenant l'agent réduisant l'hypertension Download PDF

Info

Publication number
WO2023112974A1
WO2023112974A1 PCT/JP2022/046116 JP2022046116W WO2023112974A1 WO 2023112974 A1 WO2023112974 A1 WO 2023112974A1 JP 2022046116 W JP2022046116 W JP 2022046116W WO 2023112974 A1 WO2023112974 A1 WO 2023112974A1
Authority
WO
WIPO (PCT)
Prior art keywords
hypertension
seaweed extract
antihypertensive agent
drug
trace element
Prior art date
Application number
PCT/JP2022/046116
Other languages
English (en)
Japanese (ja)
Inventor
梓 鈴木
巌 堤
Original Assignee
シード医療製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シード医療製薬株式会社 filed Critical シード医療製薬株式会社
Priority to JP2023553147A priority Critical patent/JPWO2023112974A1/ja
Publication of WO2023112974A1 publication Critical patent/WO2023112974A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a hypertension-improving agent containing a seaweed extract, and a functional food, quasi-drugs, and pharmaceuticals containing the same hypertension-improving agent.
  • Seaweed extract is known as an example of an ingredient that improves hypertension. Seaweed extract is widely used as a component of quasi-drugs, but since it is originally one of food components, it is also possible to ingest it as part of a daily diet. Therefore, seaweed extracts have been added to some health foods intended to improve blood pressure (for example, Patent Document 1).
  • Cited Document 1 improves blood fluidity due to increased deformability of red blood cells and decreased aggregation of platelets, and can be used to treat hypertension.
  • hypertension cannot be improved by blood fluidity alone. This can only be achieved by improving multiple factors such as quantity.
  • the inventors of the present invention through many years of research, have found that the seaweed extract has an auxiliary composition that promotes the blood pressure improving effect and exhibits a more remarkable hypertension improving effect, and is composed of food materials.
  • the adjuvant composition was found to be effective, leading to the perfection of formulations formulated with seaweed extracts.
  • the present invention has been made in view of such circumstances, and it is possible to express an effect equivalent to the blood pressure improving action obtained by a predetermined amount of seaweed extract with a smaller amount of seaweed extract.
  • the present invention provides a hypertension improving agent capable of
  • the present invention also provides functional foods, quasi-drugs, and pharmaceuticals containing the antihypertensive agent.
  • the hypertension improving agent according to the present invention comprises (1) a seaweed extract and an auxiliary composition that promotes the blood pressure improving action of the seaweed extract.
  • the supplementary composition comprises a trace element agent and an insoluble dietary fiber processed product.
  • the antihypertensive agent according to the present invention also has the following characteristics.
  • the seaweed extract is an extract of brown algae.
  • the brown algae should be fucus.
  • the trace element agent comprises a combination of at least two of trace element components selected from phosphorus, magnesium, manganese, zinc, iron, calcium, and selenium.
  • the trace element agent is an incinerated pulverized red alga belonging to the genus Coralaceae.
  • the processed insoluble dietary fiber is made of dietary fiber bundles having a fiber width of 20 to 80 nm and a fiber length of 120 times or more the fiber width.
  • the dosage form is powder, fine granules, granules, soft capsules, hard capsules, jelly, gummy, liquid or tablet.
  • the functional food according to the present invention contains (8) the antihypertensive agent described above.
  • the quasi-drug according to the present invention contains (9) the antihypertensive agent described above.
  • the drug according to the present invention contains (10) the antihypertensive agent described above.
  • the hypertension-improving agent comprises a seaweed extract and an auxiliary composition that promotes the blood pressure-improving action of the seaweed extract, wherein the auxiliary composition comprises: Since it is composed of a trace element agent and an insoluble dietary fiber processed product, an effect equivalent to the blood pressure improving effect obtained by a predetermined amount of seaweed extract can be expressed with a smaller amount of seaweed extract.
  • seaweed extract is an extract of brown algae, the blood pressure improving effect derived from the seaweed extract can be enjoyed more steadily.
  • the brown algae is fucus, the blood pressure improving action derived from the seaweed extract can be enjoyed more steadily.
  • the trace element agent is composed of a combination of at least two trace element components selected from phosphorus, magnesium, manganese, zinc, iron, calcium, and selenium, any of these may be used.
  • the blood pressure improving action can be promoted more remarkably compared with the case where only one or other trace elements are blended as an auxiliary composition.
  • the trace element agent is an ashed pulverized product of red algae belonging to the genus Coralaceae, it can more significantly promote the blood pressure improving action.
  • the insoluble dietary fiber processed product is made of a dietary fiber bundle having a fiber width of 20 to 80 nm and a fiber length of 120 times or more the fiber width, the blood pressure improving action can be promoted more significantly. .
  • the dosage form is powder, fine granules, granules, soft capsules, hard capsules, jelly-like, gummy-like, liquid or tablet, the age range of the ingestors from young to elderly, whether or not they are carried, etc.
  • the hypertension improving agent can be ingested in a dosage form suitable for the use environment of the ingester.
  • the functional food according to the present invention contains the above-described hypertension-improving agent, it is possible to provide a hypertension-improving agent that can be handled as a functional food.
  • the quasi-drug according to the present invention contains the hypertension-improving agent described above, it is possible to provide a hypertension-improving agent that can be handled as a quasi-drug.
  • the pharmaceutical according to the present invention contains the above-described antihypertensive agent, it is possible to provide an antihypertensive agent that can be handled as a pharmaceutical.
  • FIG. 4 is an explanatory diagram showing the results of a bad breath evaluation test
  • FIG. 3 is an explanatory diagram showing test results when the content of fucus extract was changed.
  • FIG. 4 is an explanatory diagram showing test results for an auxiliary composition
  • FIG. 2 is an explanatory diagram showing the composition of a sample subjected to a test
  • FIG. 4 is an explanatory diagram showing test results for an auxiliary composition
  • FIG. 3 is an explanatory diagram showing test results regarding insoluble dietary fiber.
  • the present invention relates to a hypertension-improving agent, particularly a hypertension-improving agent comprising a seaweed extract and an auxiliary composition that promotes the blood pressure-improving action of the seaweed extract, wherein the auxiliary composition contains trace elements
  • the present invention relates to an antihypertensive agent comprising an agent and an insoluble dietary fiber processed product.
  • seaweed extracts are said to be able to prevent or improve hypertension due to the water-soluble dietary fiber, minerals, vitamins, etc. they contain, and are used in foods and quasi-drugs.
  • seaweed extract alone was not enough to improve hypertension.
  • active ingredients eg iodine
  • the inventors of the present invention believed that the combined use with the prescribed composition would promote the digestion and absorption of the active ingredient, enhance its effect, and more remarkably exhibit the blood pressure improving action.
  • the present invention has been completed based on such ideas and findings from long-term biochemical research, and includes:
  • the improving agent is characterized in that the auxiliary composition comprises a trace element agent and an insoluble dietary fiber processed product.
  • the above description of the idea is provided for the purpose of understanding the present invention, and is the mechanism assumed by the present inventors at present. Therefore, it should be noted that it does not necessarily guarantee the correct mechanism and does not affect the patentability of the present invention.
  • the blood pressure-improving action means prevention of chronic systolic blood pressure of 135 mmHg or higher or diastolic blood pressure of 85 mmHg or higher (hereinafter referred to as hypertension) at rest (for example, when measured at home). or to improve.
  • Seaweed extracts are made by extracting the active ingredients contained in seaweeds with a solvent, and then freeze-drying or spray-drying the extract to make it powder (for example, about 2-15% moisture content).
  • seaweed examples include green algae such as green laver and sea lettuce, red algae such as agaricus and asakusanori, and brown algae such as fucus, kelp, and hijiki.
  • green algae such as green laver and sea lettuce
  • red algae such as agaricus and asakusanori
  • brown algae such as fucus, kelp, and hijiki.
  • brown algae contain more iodine than green algae and red algae. Due to recent changes in dietary habits, iodine is a component that is particularly likely to be deficient in modern people. It is preferable to use brown algae as a raw material for the seaweed extract from the viewpoint of satisfying the insufficient intake of iodine in the antihypertensive agent according to the present embodiment.
  • Iodine is a halogen element with atomic number 53 and is a trace element responsible for the production of thyroid hormones "thyroxine” and "triiodothyroxine". used.
  • Compounds such as sodium iodide and potassium iodide are also used as supplement ingredients.
  • iodide Almost all orally ingested iodide is absorbed from the gastrointestinal tract and duodenum, which are digestive organs, and moves into the blood. Some of the iodide in the blood is concentrated in the thyroid gland for thyroid hormone synthesis, but excess iodide is excreted in the urine.
  • Thyroid hormone is known to regulate the mineral balance in the body and constrict the heart and blood vessels. It is also known to be involved in sugar and lipid metabolism. If iodine is insufficient, there is a possibility that these effects cannot be enjoyed. Based on this background, the inventors found that the use of brown algae, particularly kelp, as a raw material for seaweed extracts can improve iodine deficiency, improve mineral balance, allow flexible contraction of the heart and blood vessels, and promote sugar and lipid metabolism. We believe that we can surely enjoy the improvement of function and provide a more effective antihypertensive agent.
  • fucus is used as an example of raw materials for seaweed extract.
  • Fucus is a kind of brown algae that grows on reefs. Fucus is known to contain more iodine, minerals, and alginic acid than kelp, although it has a foul odor and a harsh taste.
  • the daily intake is preferably in the range of 1.5 mg to 150 mg. That is, the daily intake of the fucus extract is preferably an amount that allows 0.003 mg to 0.3 mg of iodine to be taken. However, regardless of the iodine content, the amount of fucus extract should be no less than 1 mg dry weight.
  • the hypertension improving agent according to the present invention is not limited to the fucus extract as the seaweed extract. can be used as a raw material, and the intake can be changed as appropriate.
  • the present inventors have experimentally clarified that when the daily intake of the fucus extract is less than 1.5 mg, the blood pressure improving effect derived from the fucus extract cannot be fully enjoyed. On the other hand, taking more than 150 mg is considered unsuitable from a health standpoint, as it increases the risk of hypothyroidism, goiter, and thyrotoxicosis.
  • the trace element agent contains a combination of at least two or more selected from compounds containing phosphorus, magnesium, manganese, zinc, iron, calcium, and selenium.
  • These compounds are, for example, sodium dihydrogen phosphate, calcium dihydrogen phosphate, magnesium chloride, magnesium oxide, magnesium carbonate, trimagnesium phosphate, zinc gluconate, zinc sulfate, ferrous sulfate, ferric pyrophosphate , calcium oxide, calcium hydroxide, calcium stearate, sodium selenite, etc., which are added to foods and drinks as food additives for the purpose of nutritional enhancement.
  • the trace element agent is blended so that the total amount of phosphorus, magnesium, manganese, zinc, iron, calcium, and selenium is contained in the antihypertensive agent according to the present invention at a rate of 0.03 to 7.58% by weight.
  • magnesium oxide molecular weight: 40.30
  • calcium oxide molecular weight: 56.08
  • the trace element agents are formulated to contain 0.332 grams of magnesium oxide and 0.28 grams of calcium oxide.
  • the trace element agent may be composed by blending various metal compounds, but may be made from natural materials containing various metal compounds.
  • red algae belonging to the genus Coralaceae is used as the raw material for the trace element agent.
  • the ashing and pulverized exoskeleton (hereinafter referred to as red algae powder) mainly composed of calcium carbonate formed around the algal body during the growth process of the same red algae is used as a trace element agent.
  • red algae powder mainly composed of calcium carbonate formed around the algal body during the growth process of the same red algae is used as a trace element agent.
  • Red algae belonging to the family Coralaceae and the genus Rhododendron are seaweeds that form a hard exoskeleton like stone, and are a type of seaweed called non-gnotted coralline algae.
  • the red algae grow while incorporating minerals in the seawater, such as phosphorus, zinc, magnesium, iron, selenium, potassium, sulfur, iodine, boron, etc. into the exoskeleton, so the exoskeleton contains various minerals.
  • the exoskeleton of red algae belonging to the genus Coralaceae has a micro honeycomb structure, so it has approximately four times the surface area of a mineral (limestone) made of simple calcium carbonate. Therefore, when the red algae powder and the dry powder of the fucus extract are mixed, the dry powder of the fucus extract is incorporated into the inside of the honeycomb structure of the red algae powder, and the red algae powder exhibits a function like a hard capsule. Become. Additionally, the dry powder of fucus extract should be fine enough to be able to get into the honeycomb structure of the red algae powder.
  • red algae powder exerts a buffering effect on gastric acid. That is, in the presence of red algae powder, it is possible to suppress a rapid decrease in pH due to gastric acid, and to cause a gentle chemical reaction due to gastric acid. The cause of this is not clear at present, but the inventors believe that the synergistic action of various minerals contained in the powder is the cause.
  • the red algae powder functions as a capsule that blocks the odor and taste of the fucus extract before it is taken orally, and after it is taken orally, it dissolves in digestive juices and functions as a source of various minerals.
  • the red algae powder according to the present embodiment is blended in the hypertension improving agent at a rate of 0.1 to 20% by weight, and is blended in a range of 150 to 200 parts by weight with respect to 100 parts by weight of the seaweed extract. preferably. If the amount is less than 150 parts by weight, the fucus extract cannot be sufficiently incorporated into the honeycomb structure and the odor and taste cannot be blocked. On the other hand, if the amount exceeds 200 parts by weight, no change in effect is observed, which is not preferable from the viewpoint of cost.
  • Insoluble dietary fiber processed products are made by physically pulverizing wood and rice husks containing insoluble dietary fiber with machines such as high-pressure homogenizers, grinders, and ball mills so that the fibers have a predetermined width and length. It is.
  • freeze-drying or spray-drying is performed to remove moisture and form a powder (eg, about 2 to 15% moisture content).
  • insoluble dietary fibers that make up insoluble dietary fiber processed products include cellulose, hemicellulose, and lignin, which are the main components of the cell walls of plant cells. Further examples include chitin and chitosan, which are the main components of crustacean shells and fungal cell walls.
  • cellulose is a polymer compound in which glucose is linked in a straight chain.
  • Cellulose is present in plant cells as cellulose fibers with a width of 20 to 40 ⁇ m are formed by bundles of multiple molecular chains. Therefore, by pulverizing raw materials such as wood, it is possible to obtain fiber pieces in which cellulose fibers are finely defibrated.
  • the fiber piece has a width of 20 nm to 80 nm and a length of 120 times or more (2400 nm to 9600 nm) or more than the width, the blood pressure improving action of the antihypertensive agent according to the present embodiment can be enjoyed more steadily.
  • the insoluble dietary fiber included in this range is referred to as “nano-ized insoluble dietary fiber", and for example, when cellulose corresponds to this, it is referred to as “nano-ized cellulose”.
  • the processed insoluble dietary fiber according to this embodiment employs nano cellulose.
  • Nano cellulose dissolves in water and functions as a thickening agent and a gelling agent. Therefore, an antihypertensive agent orally ingested with water gels in the gastrointestinal tract and slows its migration to the downstream side (small intestine side) of the gastrointestinal tract.
  • the inventors found that by blending together the above-mentioned powder made from the exoskeleton of red algae belonging to the genus Coralaceae and the genus Coralaceae as a raw material, the gelled nano-cellulose has a retention time in the gastrointestinal tract of the same powder. can be extended. As a result, the digestive fluid and the red algae powder react sufficiently, and it is believed that the minerals contained in the powder are easily absorbed.
  • the nano-cellulose is preferably contained in the hypertension improving agent according to this embodiment at a rate of 0.01 to 5% by weight.
  • the content is less than 0.01% by weight, the blood pressure improving effect of the antihypertensive agent cannot be fully enjoyed.
  • the present inventors believe that the reason for this is that the seaweed extract and trace element agents do not stay in the digestive tract for a sufficient time because the nano-cellulose does not gel sufficiently.
  • the gelled nanocellulose prevents the seaweed extract and the trace element agent from coming into contact with the digestive juice, so that they are not sufficiently digested and absorbed.
  • the hypertension-improving agent according to the present invention is a hypertension-improving agent comprising a seaweed extract and an auxiliary composition that promotes the blood pressure-improving action of the seaweed extract, If the supplementary composition consists of a trace element agent and an insoluble dietary fiber processed product, an effect equivalent to the blood pressure improving action obtained by a predetermined amount of seaweed extract can be obtained with a smaller amount of seaweed extract. It is possible to provide an antihypertensive agent that can be expressed.
  • fucus is rich in iodine and minerals, it is difficult to swallow due to its foul odor and harsh taste.
  • bad odor even if soft capsules, hard capsules, etc. are orally ingested, they cause bad breath that occurs through the digestive organs as the capsules dissolve.
  • the present inventors used fucus as a raw material for the seaweed extract, used an exoskeleton formed by red algae of the genus Coralaceae as a raw material for the trace element agent of the auxiliary composition, and used an insoluble dietary fiber processed product. It has been clarified that a nano-cellulose antihypertensive agent can sufficiently reduce the foul odor and harsh taste of fucus seaweed extract and improve swallowing difficulty. In addition, it has been clarified that the gelled insoluble dietary fiber product suppresses the volatilization of offensive odors, thereby suppressing the generation of bad breath.
  • the auxiliary composition moderates the reaction between the seaweed extract and gastric acid and prolongs the retention time in the digestive tract, so that the active ingredient derived from the seaweed extract is included. It can be reliably decomposed and absorbed. As a result, it is possible to provide a hypertension-improving agent that can reliably exhibit an effect equivalent to the blood pressure improving action obtained by a predetermined amount of seaweed extract with a smaller amount of seaweed extract.
  • the dosage form of the antihypertensive agent according to the present embodiment is not particularly limited, and any dosage form such as powder, fine granules, granules, soft capsules, hard capsules, jelly-like, gummy-like, liquid or tablet may be used. can be selected.
  • hypertension-improving agent according to the present embodiment can also contain excipients, additives, auxiliary ingredients, etc. according to the dosage form, in addition to the seaweed extract and the auxiliary composition.
  • auxiliary component may be a component that imparts a further function to the antihypertensive agent or enhances the blood pressure improving action. sardine peptide and the like can be mentioned.
  • the above-mentioned antihypertensive agent can be used by blending it with functional foods, quasi-drugs, and pharmaceuticals.
  • the functional food in the present invention is a concept that includes general food that does not contain pharmaceutical ingredients and is said to contribute to the maintenance and promotion of health. It includes general foods such as so-called supplements, and foods with health claims such as foods for specified health uses, foods with nutrient claims, and foods with function claims.
  • quasi-drugs have a mild effect on the human body and are designated by the Minister of Health, Labor and Welfare. Examples include designated quasi-drugs sold at pharmacies or drug stores.
  • compositions are intended to be used for the diagnosis, treatment, or prevention of diseases. and OTC drugs that are available.
  • the hypertension improving agent according to the present embodiment will be further described below with reference to test results and the like.
  • the panelists evaluated whether or not the odor and taste of the ingested sample preparation had changed compared to the comparison preparation.
  • the odor and taste were evaluated in 4 stages (1: almost no odor, 2: slight odor, 3: odor, 4: considerable odor).
  • Each panelist was allowed to ingest the comparative preparation as appropriate when it was necessary to confirm the standards of odor and taste.
  • each of the 10 panelists diluted the fucus broth as a malodorous component in various balances and smelled it, so that the degree of odor evaluation was roughly uniform. are being trained to
  • tannin is used as an acrid taste component, and training is carried out so that the degree of acridity evaluation is roughly the same by having the subjects taste aqueous solutions that are blended in various balances. The results are shown in FIG.
  • the sample preparation was shown to be able to suppress the occurrence of bad breath compared to the comparative preparation.
  • Subjects were 10 males and females (20-60 years old, normal hypertension (systolic blood pressure 130-139 and/or diastolic blood pressure 85-89mmHg)). 30 minutes before) was continuously ingested for 4 weeks. Systolic and diastolic blood pressure was measured with a sphygmomanometer before ingestion, 4 weeks, 8 weeks, and 12 weeks after ingestion.
  • FIG. 3(a) shows systolic blood pressure and FIG. 3(b) shows diastolic blood pressure.
  • FIG. 3(a) shows systolic blood pressure
  • FIG. 3(b) shows diastolic blood pressure.
  • no antihypertensive action was confirmed for sample I1.
  • the hypertension improving action was confirmed for the other samples in the order of sample I2 ⁇ basic prescription A1 ⁇ sample I3.
  • Fig. 4(a) shows systolic blood pressure
  • Fig. 4(b) shows diastolic blood pressure.
  • the basic formulation was confirmed to have an action to improve hypertension, and a significant effect of promoting the improvement of blood pressure by the auxiliary composition was confirmed by comparison with sample X1, which does not contain red algae powder and nanoized cellulose. was done.
  • sample X1 which does not contain red algae powder and nanoized cellulose.
  • Sample X2 and Sample X3 although the antihypertensive action of the fucus extract itself was weak, it was confirmed, but the degree of improvement was comparable to that of Sample X1, which did not contain the auxiliary composition.
  • the function of the modified cellulose alone as an auxiliary composition could not be confirmed.
  • Fig. 6(a) shows systolic blood pressure
  • Fig. 6(b) shows diastolic blood pressure.
  • basic prescription A1 was confirmed to have an antihypertensive effect, but none of the samples E1 to E7 could be confirmed to have an antihypertensive effect.
  • the fiber width of the insoluble dietary fiber (sodium carboxymethyl cellulose) used is about 10 nm, and the fiber length is about 1200 nm, which is 120 times that.
  • a sample F4 having a fiber length of 100 nm and a fiber length of about 12000 nm was used for the test. The results are shown in FIG.
  • Fig. 7(a) shows systolic blood pressure
  • Fig. 7(b) shows diastolic blood pressure.
  • the sample F2 using a fiber width of about 20 nm and a fiber length of about 2400 nm, and the case of using a fiber width of about 80 nm and a fiber length of about 9600 nm like the basic prescription A1 ( Sample F3) was confirmed to have an antihypertensive effect, but none of the samples F1 and F4 could be confirmed to have an antihypertensive effect.
  • the hypertension-improving agent can exhibit an effect equivalent to the blood pressure-improving action obtained by a predetermined amount of seaweed extract with a smaller amount of seaweed extract.
  • the description of each structure mentioned above is an example of this invention, and is not limited to these.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un agent réduisant l'hypertension qui contient un extrait d'algue en une quantité plus petite par rapport à une quantité prédéfinie d'extrait d'algue pour obtenir un effet d'amélioration de la pression sanguine, et peut néanmoins présenter un effet équivalent à celle-ci. L'invention concerne également un aliment fonctionnel, un quasi-médicament et un médicament contenant chacun l'agent réduisant l'hypertension. L'agent réduisant l'hypertension contient un extrait d'algue et une composition auxiliaire qui renforce l'effet d'amélioration de la pression sanguine de l'extrait d'algue. La composition auxiliaire comprend un agent oligo-élément et une fibre alimentaire insoluble traitée. L'aliment fonctionnel, le quasi-médicament et le médicament contiennent chacun l'agent réduisant l'hypertension précité.
PCT/JP2022/046116 2021-12-14 2022-12-14 Agent réduisant l'hypertension contenant un extrait d'algue, et aliment fonctionnel, quasi-médicament et médicament contenant l'agent réduisant l'hypertension WO2023112974A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023553147A JPWO2023112974A1 (fr) 2021-12-14 2022-12-14

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-202737 2021-12-14
JP2021202737 2021-12-14

Publications (1)

Publication Number Publication Date
WO2023112974A1 true WO2023112974A1 (fr) 2023-06-22

Family

ID=86774343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/046116 WO2023112974A1 (fr) 2021-12-14 2022-12-14 Agent réduisant l'hypertension contenant un extrait d'algue, et aliment fonctionnel, quasi-médicament et médicament contenant l'agent réduisant l'hypertension

Country Status (2)

Country Link
JP (1) JPWO2023112974A1 (fr)
WO (1) WO2023112974A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0416164A (ja) * 1990-05-10 1992-01-21 Morishita Jintan Kk 海藻ミネラルの製造方法
JPH10120578A (ja) * 1996-10-24 1998-05-12 Takeshi Ogura 海洋ミネラル成分からなる治療及び／または予防剤
JP2003079340A (ja) * 2001-07-06 2003-03-18 Tamiya Yamamura 体質改善健康食品
JP2006320320A (ja) * 2005-04-22 2006-11-30 Meiji Univ 海藻高温抽出組成物、海藻熱処理組成物及びそれらの製造方法並びに海藻高温抽出組成物又は海藻熱処理組成物を含む調味料、化粧料、食品及び健康食品
JP2008086217A (ja) * 2006-09-29 2008-04-17 Sanki Shoji Kk 健康食品
CN102552471A (zh) * 2012-02-23 2012-07-11 淄博金硕生物科技有限公司 一种具有降压、降血脂作用的中药制剂或中药保健品
JP2019041661A (ja) * 2017-08-31 2019-03-22 株式会社シェフコ 健康食品
JP2019070031A (ja) * 2013-03-14 2019-05-09 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0416164A (ja) * 1990-05-10 1992-01-21 Morishita Jintan Kk 海藻ミネラルの製造方法
JPH10120578A (ja) * 1996-10-24 1998-05-12 Takeshi Ogura 海洋ミネラル成分からなる治療及び／または予防剤
JP2003079340A (ja) * 2001-07-06 2003-03-18 Tamiya Yamamura 体質改善健康食品
JP2006320320A (ja) * 2005-04-22 2006-11-30 Meiji Univ 海藻高温抽出組成物、海藻熱処理組成物及びそれらの製造方法並びに海藻高温抽出組成物又は海藻熱処理組成物を含む調味料、化粧料、食品及び健康食品
JP2008086217A (ja) * 2006-09-29 2008-04-17 Sanki Shoji Kk 健康食品
CN102552471A (zh) * 2012-02-23 2012-07-11 淄博金硕生物科技有限公司 一种具有降压、降血脂作用的中药制剂或中药保健品
JP2019070031A (ja) * 2013-03-14 2019-05-09 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
JP2019041661A (ja) * 2017-08-31 2019-03-22 株式会社シェフコ 健康食品

Also Published As

Publication number Publication date
JPWO2023112974A1 (fr) 2023-06-22

Similar Documents

Publication Publication Date Title
US20090169682A1 (en) Functional Masticatory Material, Method Of Producing The Same And Method Of Using The Same
EP2271367B1 (fr) Accélérateur d'absorption de minéraux et agent ou composition alimentaire améliorant l'anémie ferriprive
JP2007131620A (ja) 機能性咀嚼物及びその製造方法並びにその使用方法
KR101614574B1 (ko) 탱자 발효물에 의한 비만개선효과물질의 조성
KR100654904B1 (ko) 생약 추출물을 포함하는 항염 또는 연골 재생용 조성물
RU2446815C1 (ru) Биологически активная добавка к пище для нормализации функции щитовидной железы
KR101217080B1 (ko) 생약 추출물을 유효성분으로 포함하는 숙취 해소용 조성물 및 그의 제조 방법
CN114711336A (zh) 避免抗微生物剂抗性的抗腹泻制剂
WO2023112974A1 (fr) Agent réduisant l'hypertension contenant un extrait d'algue, et aliment fonctionnel, quasi-médicament et médicament contenant l'agent réduisant l'hypertension
KR101721145B1 (ko) Ｌ-카르니틴 구연산 마그네슘을 포함하는 배변촉진 겸용 다이어트용 식품 조성물
JP2007246541A (ja) 機能性咀嚼物及びその製造方法
JP5156330B2 (ja) 脂肪組織重量減少剤
CN109673906A (zh) 一种复合膳食纤维粉及其制备方法
KR20200043555A (ko) 다이어트용 보조식품 조성물
RU2205655C1 (ru) Средство для профилактики и лечения мочекаменной болезни
CN101450074B (zh) 一种明显改善胃肠道功能、防治便秘的组合物
KR100654903B1 (ko) 인진, 갈근 및 차조기를 포함하는 항염 또는 연골 재생용 조성물
KR20050101143A (ko) 글루코사민을 포함하는 퇴행성관절염 예방 및 개선을 위한조성물 및 그 제조방법
WO2022013581A1 (fr) Supplément nutritionnel, approprié pour une administration orale, comprenant de la dihydromyricétine, de la choline et une ou plusieurs vitamines ayant une activité antioxydante, pour une utilisation dans le maintien d'une fonction hépatique normale
JP2012170342A (ja) 味質改善剤
US20220218776A1 (en) Composition for use in a method for prevention or treatment of maltnutrition in a subject suffering from a chronic inflammatory bowel diseases
JP2008120771A (ja) 便秘改善剤
KR100734944B1 (ko) 젖산칼슘 및 미강을 주재로 한 기능성 건강식품 조성물
KR20150010034A (ko) 미역귀차 조성물
JP7157496B1 (ja) 経口組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22907497

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023553147

Country of ref document: JP